| Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08 CJ Allegra, G Yothers, MJ O'Connell, S Sharif, NJ Petrelli, LH Colangelo, ... Journal of Clinical Oncology 29 (1), 11-16, 2011 | 751 | 2011 |
| Novel allogeneic granulocyte-macrophage colony-stimulating factor–secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation EM Jaffee, RH Hruban, B Biedrzycki, D Laheru, K Schepers, PR Sauter, ... Journal of Clinical Oncology 19 (1), 145-156, 2001 | 695 | 2001 |
| Detection of breast cancer micrometastases in axillary lymph nodes by using polymerase chain reaction A Schoenfeld, Y Luqmani, D Smith, S O'reilly, S Shousha, HD Sinnett, ... Cancer research 54 (11), 2986-2990, 1994 | 358 | 1994 |
| Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III … CJ Allegra, G Yothers, MJ O'Connell, S Sharif, LH Colangelo, SH Lopa, ... Journal of Clinical Oncology 27 (20), 3385-3390, 2009 | 308 | 2009 |
| The association of pre-treatment neutrophil to lymphocyte ratio with overall survival in patients with glioblastoma multiforme RM Bambury, MY Teo, DG Power, A Yusuf, S Murray, JE Battley, C Drake, ... Journal of neuro-oncology 114, 149-154, 2013 | 237 | 2013 |
| A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08 N Wolmark, G Yothers, MJ O’Connell, S Sharif, JN Atkins, TE Seay, ... J Clin Oncol 27 (18 suppl), 6s, 2009 | 222 | 2009 |
| A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer EC Dees, S O'reilly, SN Goodman, S Sartorius, MA Levine, RJ Jones, ... Cancer investigation 18 (6), 521-529, 2000 | 215 | 2000 |
| ICORG 10-14: NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric junction International Study (Neo-AEGIS) JV Reynolds, SR Preston, B O’neill, L Baeksgaard, SM Griffin, C Mariette, ... BMC cancer 17, 1-10, 2017 | 182 | 2017 |
| Herceptin (trastuzamab) in advanced breast cancer J Stebbing, E Copson, S O’reilly Cancer treatment reviews 26 (4), 287-290, 2000 | 160 | 2000 |
| Phase I and pharmacologic study of topotecan in patients with impaired renal function. S O'Reilly, EK Rowinsky, W Slichenmyer, RC Donehower, AA Forastiere, ... Journal of clinical oncology 14 (12), 3062-3073, 1996 | 146 | 1996 |
| Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial M Colleoni, W Luo, P Karlsson, J Chirgwin, S Aebi, G Jerusalem, P Neven, ... The lancet oncology 19 (1), 127-138, 2018 | 117 | 2018 |
| A Phase I Clinical Trial of Lethally Irradiated Allogeneic Pancreatic Tumor Cells Transfected with the GM-CSF Gene for the Treatment of Pancreatic Adenocarcinoma. The Johns … EM Jaffee, R Abrams, J Cameron, R Donehower, M Duerr, J Gossett, ... Human gene therapy 9 (13), 1951-1971, 1998 | 102 | 1998 |
| Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function S O'Reilly, E Rowinsky, W Slichenmyer, RC Donehower, A Forastiere, ... JNCI: Journal of the National Cancer Institute 88 (12), 817-824, 1996 | 98 | 1996 |
| Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open … JV Reynolds, SR Preston, B O'Neill, MA Lowery, L Baeksgaard, T Crosby, ... The Lancet Gastroenterology & Hepatology 8 (11), 1015-1027, 2023 | 92 | 2023 |
| A phase I and pharmacokinetic study of short infusions of UCN-01 in patients with refractory solid tumors EC Dees, SD Baker, S O'Reilly, MA Rudek, SB Davidson, C Aylesworth, ... Clinical cancer research 11 (2), 664-671, 2005 | 85 | 2005 |
| Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil SD Baker, RB Diasio, S O’Reilly, VS Lucas, SP Khor, SE Sartorius, ... Journal of clinical oncology 18 (4), 915-915, 2000 | 85 | 2000 |
| Clinical guidelines for managing topotecan-related hematologic toxicity D Armstrong, S O'Reilly The Oncologist 3 (1), 4-10, 1998 | 77 | 1998 |
| Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study. S O'Reilly, GF Fleming, SD Barker, JR Walczak, MA Bookman, ... Journal of clinical oncology 15 (1), 177-186, 1997 | 77 | 1997 |
| The clinical status of irinotecan (CPT-11), a novel water soluble camptothecin analogue: 1996 S O'Reilly, EK Rowinsky Critical reviews in oncology/hematology 24 (1), 47-70, 1996 | 73 | 1996 |
| Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumors EI Heath, S O'Reilly, R Humphrey, P Sundaresan, RC Donehower, ... Cancer chemotherapy and pharmacology 48, 269-274, 2001 | 66 | 2001 |